Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks.
Anti-tumor necrosis factor (anti-TNF) therapy used to treat pregnant patients with inflammatory bowel disease (IBD) has been linked with lower birth weight, shorter gestational term, and in some studies, more frequent birth defects or spontaneous abortion.
Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks in the same population.
The observational study was conducted among 20 pregnant women who were treated with biosimilar infliximab. Researchers compiled data on disease activity, prior treatment, and newborn outcome, as well as blood levels of the anti-TNF agent.
Of the 20 women studied, 16 had Crohn disease, and 4 had ulcerative colitis. Patients’ mean age was 28.7 (±4.1), and 55% (n = 11) were pregnant for the first time.
At the time they conceived, 30% (6) of the patients had active disease, and 65% (n = 13) were in remission. One patient was newly diagnosed with acute severe colitis after having conceived. Other than the last patient, all women had already received infliximab treatment prior to pregnancy.
Researchers recorded 19 live births, with a mean weight 3305 g (±493 g), 18 of which were at term. One was both preterm and had a low birth weight. One pregnancy was spontaneously aborted.
In addition, researchers found that disease activity at conception was associated with both lower birth weight; mean birthweight was 3549 g (±392 g) in the remission group versus 2921 g (±390 g) in the active disease group, respectively (P =.0043).
Although researchers note that findings were limited by the small study size, no new safety concerns were found in pregnant women treated with biosimilar infliximab. In addition, according to the study authors, this was the first report of pregnancy outcomes in women treated with biosimilar infliximab.
Reference
Kolar M, Duricova D, Bortlik M, et al. Pregnancy outcomes in women with IBD treatment with biosimilar infliximab. Presented at the European Crohn's and Colitis Organisation Congress 2018 meeting, February 14-17, 2018; Vienna, Austria. Abstract P614.
ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/p614-pregnancy-outcomes-in-women-with-ibd-treated-with-biosimilar-infliximab.html
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.